Corrigendum to “IL-10-producing regulatory B cells are decreased in patients with psoriasis” [J. Dermatol. Sci. 81 (2016) 93–100] (S0923181115300748)(10.1016/j.jdermsci.2015.11.003);IL-10-producing regulatory B cells are decreased in patients with psoriasis

Journal of Dermatological Science

Volumn 81, Issue 2, 2016, Pages 93-100

  Hayashi, Mitsuha ^a   Yanaba, Koichi ^a   Umezawa, Yoshinori ^a   Yoshihara, Yuki ^a   Kikuchi, Sota ^a   Ishiuji, Yozo ^a   Saeki, Hidehisa ^b   Nakagawa, Hidemi ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NIPPON MEDICAL SCHOOL GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

B cells; B cell activating factor; B10 cells; IL 10; Psoriasis; Regulatory B cells

Indexed keywords

B CELL ACTIVATING FACTOR; B7 ANTIGEN; CD86 ANTIGEN; FAS ANTIGEN; INTERLEUKIN 10; BIOLOGICAL MARKER; IL10 PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT; LEUKOCYTE ANTIGEN;

ARTICLE; B LYMPHOCYTE; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INTERLEUKIN 10 PRODUCING REGULATORY B CELL; MEMORY CELL; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIASIS; STEM CELL; BLOOD; CASE CONTROL STUDY; CELL CULTURE; DOWN REGULATION; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE COUNT; METABOLISM; PHENOTYPE; PROCEDURES; TIME FACTOR; TREATMENT OUTCOME;

ANTIGENS, CD; B-LYMPHOCYTES, REGULATORY; BIOMARKERS; CASE-CONTROL STUDIES; CELLS, CULTURED; DOWN-REGULATION; FLOW CYTOMETRY; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-10; LYMPHOCYTE COUNT; PHENOTYPE; PSORIASIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84957554824     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2017.01.010     Document Type: Erratum

References (33)

1. Nestle F.O., Kaplan D.H., Barker J. Psoriasis. N. Engl. J. Med. 2009, 361:496-509.
2. Shlomchik M.J., Madaio M.P., Ni D., Trounstine M., Huszar D. The role of B cells in lpr/lpr-induced autoimmunity. J. Exp. Med. 1994, 180:1295-1306.
3. Bouaziz J.D., Yanaba K., Tedder T.F. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol. Rev. 2008, 224:201-214.
4. + phenotype controls T cell-dependent inflammatory responses. Immunity 2008, 28:639-650.
5. Matsushita T., Yanaba K., Bouaziz J.D., Fujimoto M., Tedder T.F. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J. Clin. Invest. 2008, 118:3420-3430.
6. Yanaba K., Yoshizaki A., Asano Y., Kadono T., Tedder T.F., Sato S. IL-10-producing regulatory B10 cells inhibit intestinal injury in a mouse model. Am. J. Pathol. 2011, 178:735-743.
7. Yanaba K., Bouaziz J.D., Matsushita T., Tsubata T., Tedder T.F. The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. J. Immunol. 2009, 182:7459-7472.
8. hi B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity 2010, 32:129-140.
9. Iwata Y., Matsushita T., Horikawa M., Dilillo D.J., Yanaba K., Venturi G.M., et al. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 2011, 117:530-541.
10. + T-cell activation in vitro. Eur. J. Immunol. 2010, 40:2686-2691.
11. H17 differentiation. Sci. Transl. Med. 2013, 5:173ra23.
12. Daien C.I., Gailhac S., Mura T., Audo R., Combe B., Hahne M., et al. Regulatory B10 cells are decreased in patients with rheumatoid arthritis and are inversely correlated with disease activity. Arthritis Rheumatol. 2014, 66:2037-2046.
13. Gao N., Dresel J., Eckstein V., Gellert R., Storch H., Venigalla R.K., et al. Impaired suppressive capacity of activation-induced regulatory B cells in systemic lupus erythematosus. Arthritis Rheumatol. 2014, 66:2849-2861.
14. hi regulatory B cells in patients with pemphigus. Br. J. Dermatol. 2015, 172:101-110.
15. Saussine A., Tazi A., Feuillet S., Rybojad M., Juillard C., Bergeron A., et al. Active chronic sarcoidosis is characterized by increased transitional blood B cells, increased IL-10-producing regulatory B cells and high BAFF levels. PLoS One 2012, 7:e43588.
16. Todd S.K., Pepper R.J., Draibe J., Tanna A., Pusey C.D., Mauri C., et al. Regulatory B cells are numerically but not functionally deficient in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford) 2014, 53:1693-1703.
17. Yanaba K., Kamata M., Ishiura N., Shibata S., Asano Y., Tada Y., et al. Regulatory B cells suppress imiquimod-induced, psoriasis-like skin inflammation. J. Leukoc. Biol. 2013, 94:563-573.
18. Asadullah K., Sterry W., Stephanek K., Jasulaitis D., Leupold M., Audring H., et al. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J. Clin. Invest. 1998, 101:783-794.
19. Weiss E., Mamelak A.J., La Morgia S., Wang B., Feliciani C., Tulli A., et al. The role of interleukin 10 in the pathogenesis and potential treatment of skin diseases. J. Am. Acad. Dermatol. 2004, 50:657-675. quiz 76-8.
20. Dass S., Vital E.M., Emery P. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum. 2007, 56:2715-2718.
21. Mielke F., Schneider-Obermeyer J., Dorner T. Onset of psoriasis with psoriatic arthropathy during rituximab treatment of non-Hodgkin lymphoma. Ann. Rheum. Dis. 2008, 67:1056-1057.
22. Kalled S.L. Impact of the BAFF/BR3 axis on B cell survival, germinal center maintenance and antibody production. Semin. Immunol. 2006, 18:290-296.
23. Wang J., Watanabe T. Expression and function of Fas during differentiation and activation of B cells. Int. Rev. Immunol. 1999, 18:367-379.
24. Cheema G.S., Roschke V., Hilbert D.M., Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 2001, 44:1313-1319.
25. Zhang J., Roschke V., Baker K.P., Wang Z., Alarcon G.S., Fessler B.J., et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J. Immunol. 2001, 166:6-10.
26. Matsushita T., Hasegawa M., Yanaba K., Kodera M., Takehara K., Sato S. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum. 2006, 54:192-201.
27. Samoud-El Kissi S., Galai Y., Sghiri R., Kenani N., Ben Alaya-Bouafif N., Boukadida J., et al. BAFF is elevated in serum of patients with psoriasis: association with disease activity. Br. J. Dermatol. 2008, 159:765-768.
28. Yang M., Sun L., Wang S., Ko K.H., Xu H., Zheng B.J., et al. Novel function of B cell-activating factor in the induction of IL-10-producing regulatory B cells. J. Immunol. 2010, 184:3321-3325.
29. Saulep-Easton D., Vincent F.B., Quah P.S., Wei A., Ting S.B., Croce C.M., et al. The BAFF receptor TACI controls IL-10 production by regulatory B cells and CLL B cells. Leukemia 2016, 30:163-172.
30. Jacobi A.M., Huang W., Wang T., Freimuth W., Sanz I., Furie R., et al. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2010, 62:201-210.
31. Pontarini E., Fabris M., Quartuccio L., Cappeletti M., Calcaterra F., Roberto A., et al. Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren's syndrome. Rheumatology (Oxford) 2015, 54:1429-1434.
32. Yoshizaki A., Miyagaki T., DiLillo D.J., Matsushita T., Horikawa M., Kountikov E.I., et al. Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. Nature 2012, 491:264-268.
33. Asadullah K., Sterry W., Volk H.D. Interleukin-10 therapy-review of a new approach. Pharmacol. Rev. 2003, 55:241-269.